Literature DB >> 34707258

Advancing the global public health agenda for NAFLD: a consensus statement.

Jeffrey V Lazarus1,2, Henry E Mark3, Quentin M Anstee4,5, Juan Pablo Arab6, Rachel L Batterham7, Laurent Castera8, Helena Cortez-Pinto9, Javier Crespo10, Kenneth Cusi11, M Ashworth Dirac12, Sven Francque13,14, Jacob George15, Hannes Hagström16, Terry T-K Huang17, Mona H Ismail18, Achim Kautz19, Shiv Kumar Sarin20, Rohit Loomba21,22, Veronica Miller23, Philip N Newsome24, Michael Ninburg25, Ponsiano Ocama26, Vlad Ratziu27, Mary Rinella28, Diana Romero29, Manuel Romero-Gómez30, Jörn M Schattenberg31, Emmanuel A Tsochatzis32,33, Luca Valenti34,35, Vincent Wai-Sun Wong36, Yusuf Yilmaz37,38, Zobair M Younossi39, Shira Zelber-Sagi40,41.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics - from epidemiology, awareness, care and treatment to public health policies and leadership - that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD.
© 2021. Springer Nature Limited.

Entities:  

Mesh:

Year:  2021        PMID: 34707258     DOI: 10.1038/s41575-021-00523-4

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  124 in total

Review 1.  Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future.

Authors:  Ana Ruth Araújo; Natalia Rosso; Giorgio Bedogni; Claudio Tiribelli; Stefano Bellentani
Journal:  Liver Int       Date:  2018-02       Impact factor: 5.828

2.  Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls.

Authors:  Hannes Hagström; Patrik Nasr; Mattias Ekstedt; Ulf Hammar; Linnea Widman; Per Stål; Rolf Hultcrantz; Stergios Kechagias; Martin Henriksson
Journal:  Clin Gastroenterol Hepatol       Date:  2019-10-18       Impact factor: 11.382

3.  The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

Authors:  Zobair M Younossi; Quentin M Anstee; Vincent Wai-Sun Wong; Michael Trauner; Eric J Lawitz; Stephen A Harrison; Marianne Camargo; Kathryn Kersey; G Mani Subramanian; Robert P Myers; Maria Stepanova
Journal:  Gastroenterology       Date:  2020-12-08       Impact factor: 22.682

4.  Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.

Authors:  Jamie O'Hara; Alan Finnegan; Harpal Dhillon; Leonardo Ruiz-Casas; Gabriel Pedra; Bethany Franks; George Morgan; Vanessa Hebditch; Bengt Jönsson; Mzwandile Mabhala; Tatjana Reic; Ingo Van Thiel; Vlad Ratziu; Manuel Romero-Gomez; Elisabetta Bugianesi; Jörn M Schattenberg; Quentin M Anstee
Journal:  JHEP Rep       Date:  2020-07-15

5.  Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Srikar Mapakshi; Yamini Natarajan; Maneerat Chayanupatkul; Peter A Richardson; Liang Li; Roxanne Desiderio; Aaron P Thrift; Steven M Asch; Jinna Chu; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

6.  The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.

Authors:  Zobair M Younossi; Deirdre Blissett; Robert Blissett; Linda Henry; Maria Stepanova; Youssef Younossi; Andrei Racila; Sharon Hunt; Rachel Beckerman
Journal:  Hepatology       Date:  2016-09-26       Impact factor: 17.425

Review 7.  Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis.

Authors:  Jörn M Schattenberg; Jeffrey V Lazarus; Philip N Newsome; Lawrence Serfaty; Alessio Aghemo; Salvador Augustin; Emmanuel Tsochatzis; Victor de Ledinghen; Elisabetta Bugianesi; Manuel Romero-Gomez; Heike Bantel; Stephen D Ryder; Jerome Boursier; Vincent Leroy; Javier Crespo; Laurent Castera; Lefteris Floros; Vincenzo Atella; Jorge Mestre-Ferrandiz; Rachel Elliott; Achim Kautz; Alice Morgan; Sally Hartmanis; Sharad Vasudevan; Lynne Pezzullo; Aldo Trylesinski; Sandrine Cure; Victoria Higgins; Vlad Ratziu
Journal:  Liver Int       Date:  2021-03-18       Impact factor: 5.828

8.  Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL).

Authors:  Pegah Golabi; Munkhzul Otgonsuren; Rebecca Cable; Sean Felix; Aaron Koenig; Mehmet Sayiner; Zobair M Younossi
Journal:  Health Qual Life Outcomes       Date:  2016-02-09       Impact factor: 3.186

Review 9.  Natural History of NAFLD/NASH.

Authors:  Mattias Ekstedt; Patrik Nasr; Stergios Kechagias
Journal:  Curr Hepatol Rep       Date:  2017-11-13

10.  Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis.

Authors:  Lorraine McSweeney; Matthew Breckons; Gulnar Fattakhova; Yemi Oluboyede; Luke Vale; Laura Ternent; Maria-Magdalena Balp; Lynda Doward; Clifford A Brass; Fiona Beyer; Arun Sanyal; Quentin M Anstee
Journal:  JHEP Rep       Date:  2020-03-06
View more
  31 in total

1.  Natural history of NAFLD: knowns and unknowns.

Authors:  Emmanuel A Tsochatzis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-03       Impact factor: 46.802

2.  Paving the way: the road to be taken for proper NAFLD health care.

Authors: 
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-01       Impact factor: 46.802

Review 3.  Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Melanie J Davies; Vanita R Aroda; Billy S Collins; Robert A Gabbay; Jennifer Green; Nisa M Maruthur; Sylvia E Rosas; Stefano Del Prato; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Tsvetalina Tankova; Apostolos Tsapas; John B Buse
Journal:  Diabetologia       Date:  2022-09-24       Impact factor: 10.460

4.  Nonalcoholic Steatohepatitis, Peroxisome Proliferator-Activated Receptors and Our Good Glitazar: Proof of the Pudding is in the Eating.

Authors:  Anil C Anand; Subrata K Acharya
Journal:  J Clin Exp Hepatol       Date:  2022-01-25

Review 5.  Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.

Authors:  Gashaw Hassen; Abhishek Singh; Gizeshwork Belete; Nidhi Jain; Ivonne De la Hoz; Genesis P Camacho-Leon; Nitsuh K Dargie; Keila G Carrera; Tadesse Alemu; Sharan Jhaveri; Nebiyou Solomon
Journal:  Cureus       Date:  2022-05-30

6.  Identification of the Potential Molecular Mechanisms Linking RUNX1 Activity with Nonalcoholic Fatty Liver Disease, by Means of Systems Biology.

Authors:  Laia Bertran; Ailende Eigbefoh-Addeh; Marta Portillo-Carrasquer; Andrea Barrientos-Riosalido; Jessica Binetti; Carmen Aguilar; Javier Ugarte Chicote; Helena Bartra; Laura Artigas; Mireia Coma; Cristóbal Richart; Teresa Auguet
Journal:  Biomedicines       Date:  2022-06-03

Review 7.  Liver Diseases in Latin America: Current Status, Unmet Needs, and Opportunities for Improvement.

Authors:  Luis Antonio Díaz; Gustavo Ayares; Jorge Arnold; Francisco Idalsoaga; Oscar Corsi; Marco Arrese; Juan Pablo Arab
Journal:  Curr Treat Options Gastroenterol       Date:  2022-06-16

Review 8.  NAFLD: Mechanisms, Treatments, and Biomarkers.

Authors:  Fatiha Nassir
Journal:  Biomolecules       Date:  2022-06-13

9.  The association between non-alcoholic fatty liver disease and serum ferritin levels in American adults.

Authors:  Naibin Yang; Yi Lu; Liwen Cao; Mingqin Lu
Journal:  J Clin Lab Anal       Date:  2022-01-07       Impact factor: 2.352

Review 10.  Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.

Authors:  Daryl Ramai; Antonio Facciorusso; Erika Vigandt; Bryan Schaf; Waleed Saadedeen; Aditya Chauhan; Sara di Nunzio; Aashni Shah; Luca Giacomelli; Rodolfo Sacco
Journal:  Cells       Date:  2021-12-02       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.